125 related articles for article (PubMed ID: 31098918)
1. The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting System.
Muñoz MA; Dal Pan GJ
Drug Saf; 2019 Oct; 42(10):1199-1201. PubMed ID: 31098918
[No Abstract] [Full Text] [Related]
2. Report slams US FDA's drug safety reform efforts.
Bristol N
Lancet; 2007 Mar; 369(9567):1072. PubMed ID: 17405202
[No Abstract] [Full Text] [Related]
3. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
Szarfman A; Machado SG; O'Neill RT
Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug events and the Freedom of Information Act: an apple in Eden.
Stang PE; Fox JL
Ann Pharmacother; 1992 Feb; 26(2):238-43. PubMed ID: 1554939
[TBL] [Abstract][Full Text] [Related]
5. Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004.
Zinderman CE; Landow L; Wise RP
J Vasc Surg; 2006 May; 43(5):1004-9. PubMed ID: 16678697
[TBL] [Abstract][Full Text] [Related]
6. FDA's sentinel network: a monumental task.
Young D
Am J Health Syst Pharm; 2007 Apr; 64(8):800-1. PubMed ID: 17420189
[No Abstract] [Full Text] [Related]
7. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
Rogers JR; Sarpatwari A; Desai RJ; Bohn JM; Khan NF; Kesselheim AS; Fischer MA; Gagne JJ; Connolly JG
Drug Saf; 2019 Jan; 42(1):85-93. PubMed ID: 30066315
[TBL] [Abstract][Full Text] [Related]
8. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System.
Pistor M; Hoepner AGF; Lin Y; Jung S; Bassetti CL; Chan A; Salmen A; Hoepner R
Ann Rheum Dis; 2021 Dec; 80(12):1633-1635. PubMed ID: 34285050
[No Abstract] [Full Text] [Related]
10. Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System.
Harpaz R; Haerian K; Chase HS; Friedman C
AMIA Annu Symp Proc; 2010 Nov; 2010():281-5. PubMed ID: 21346985
[TBL] [Abstract][Full Text] [Related]
11. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities.
Ursem CJ; Kruhlak NL; Contrera JF; MacLaughlin PM; Benz RD; Matthews EJ
Regul Toxicol Pharmacol; 2009 Jun; 54(1):1-22. PubMed ID: 19422096
[TBL] [Abstract][Full Text] [Related]
12. Extended likelihood ratio test-based methods for signal detection in a drug class with application to FDA's adverse event reporting system database.
Zhao Y; Yi M; Tiwari RC
Stat Methods Med Res; 2018 Mar; 27(3):876-890. PubMed ID: 27142982
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system.
Rossi AC; Knapp DE
JAMA; 1984 Aug 24-31; 252(8):1030-3. PubMed ID: 6748207
[TBL] [Abstract][Full Text] [Related]
14. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
Clark JA; Humphries JE; Crean S; Reynolds MW
Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
[TBL] [Abstract][Full Text] [Related]
15. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System.
Min J; Osborne V; Kowalski A; Prosperi M
Drug Saf; 2018 Mar; 41(3):313-320. PubMed ID: 29098610
[TBL] [Abstract][Full Text] [Related]
16. FDA's adverse-event surveillance needs improvement, advisers say.
Traynor K
Am J Health Syst Pharm; 2005 Jul; 62(13):1336, 1338, 1340. PubMed ID: 15972368
[No Abstract] [Full Text] [Related]
17. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
[TBL] [Abstract][Full Text] [Related]
18. Physicians' liability for adverse drug reactions.
Kaufman MB; Stoukides CA; Campbell NA
South Med J; 1994 Aug; 87(8):780-4. PubMed ID: 8052883
[TBL] [Abstract][Full Text] [Related]
19. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
20. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
